Xencor, Inc.

Stocks

Real-time Estimate Cboe BZX 14:12:27 2026-10-26 EDT			5-day change	1st Jan Change
30.10 ^USD	+19.56%		+30.29%	+97.35%

01:57pm	Top Midday Gainers	MT
11:38am	Wedbush Adjusts Price Target on Xencor to $45 From $30, Maintains Outperform Rating	MT

Published on 10/26/2026 at 08:50 am EDT - Modified on 10/26/2026 at 12:53 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Xencor ESMO 2026 webcast. [Operator Instructions] Also as a reminder, this conference call is being recorded today. If you

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

01:57pm	Top Midday Gainers	MT
11:38am	Wedbush Adjusts Price Target on Xencor to $45 From $30, Maintains Outperform Rating	MT
08:50am	Xencor, Inc. - Special Call
07:33am	Top Premarket Gainers	MT
06:49am	Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate	MT
10-25	Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors	CI
09-25	Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says	MT
09-21	BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating	MT
09-01	Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT
08-06	RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating	MT
08-05	Earnings Flash (XNCR) Xencor, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $18.9M	MT
08-05	Xencor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Xencor Shares Rise After Settlement Deal With Alexion	MT
07-17	Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise	MT

Duration

Period

Sector